Physician profile
Ren Zhou
NPI 1942257290
$2,145.52
in general payments reported to CMS, 2019-2025
16 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $190 · 2021: $281 · 2022: $725 · 2023: $123 · 2024: $254 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $587.69 | 2019-2025 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.19 | 2019-2022 | |
| Novo Nordisk INC | $153.56 | 2021-2022 | |
| Amarin Pharma, INC. | $143.30 | 2019-2022 | |
| Pharming Healthcare, INC. | $130.08 | 2024 | Ruconest |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Intra-Sana Laboratories | $111.11 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Corcept Therapeutics | $107.92 | 2023 | Korlym |
| Amgen INC. | $100.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.82 | 2022-2025 | Wainua |
| Abbvie INC. | $71.20 | 2021-2024 | Vraylar |
| Allergan, INC. | $48.97 | 2019-2020 | |
| Lilly USA, LLC | $37.23 | 2020 | |
| Merck Sharp & Dohme LLC | $24.83 | 2019-2020 | |
| Glaxosmithkline, LLC. | $15.33 | 2025 | Shingrix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ren Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.